FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer By Ogkologos - January 17, 2025 794 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ADRIATIC study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without... September 1, 2020 FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... July 19, 2024 Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic... May 14, 2026 Children with Acute Lymphoblastic Leukemia Can Skip Radiation to the Brain November 25, 2019 Load more HOT NEWS Getting through the Holidays-With a Little Help From Oncolink Working towards equal cancer care for everyone Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful...
